36 chief innovation officers to know | 2024
Becker’s Healthcare is proud to spotlight 36 trailblazing chief innovation officers from hospitals and health systems across the nation.
Related Articles
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
This Review describes why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of central nervous system tumors.
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
2024 Most Read Articles | Blood | American Society of Hematology
2024 Most Read Articles | Blood | American Society of Hematology Top Ten Most Read Articles in 2024 Blood is pleased to announce the following…
Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer
SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.
State Cancer Profiles
State Cancer Profiles is an interactive map engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was…
